BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33903672)

  • 1. A novel cystathionine γ-lyase inhibitor, I194496, inhibits the growth and metastasis of human TNBC via downregulating multiple signaling pathways.
    Liu Y; Wang L; Zhang X; Deng Y; Pan L; Li H; Shi X; Wang T
    Sci Rep; 2021 Apr; 11(1):8963. PubMed ID: 33903672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cystathionine‑γ‑lyase promotes the metastasis of breast cancer via the VEGF signaling pathway.
    Wang L; Shi H; Liu Y; Zhang W; Duan X; Li M; Shi X; Wang T
    Int J Oncol; 2019 Aug; 55(2):473-487. PubMed ID: 31173185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. I157172, a novel inhibitor of cystathionine γ-lyase, inhibits growth and migration of breast cancer cells via SIRT1-mediated deacetylation of STAT3.
    Wang L; Shi H; Zhang X; Zhang X; Liu Y; Kang W; Shi X; Wang T
    Oncol Rep; 2019 Jan; 41(1):427-436. PubMed ID: 30365149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulation of cystathionine γ-lyase (CSE)/hydrogen sulfide pathway contributes to ox-LDL-induced inflammation in macrophage.
    Wang XH; Wang F; You SJ; Cao YJ; Cao LD; Han Q; Liu CF; Hu LF
    Cell Signal; 2013 Nov; 25(11):2255-62. PubMed ID: 23872072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis.
    Gautam J; Banskota S; Lee H; Lee YJ; Jeon YH; Kim JA; Jeong BS
    Exp Mol Med; 2018 Sep; 50(9):1-14. PubMed ID: 30185799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Inhibition of Endogenous Hydrogen Sulfide Attenuates Breast Cancer Progression.
    Khan NH; Wang D; Wang W; Shahid M; Khattak S; Ngowi EE; Sarfraz M; Ji XY; Zhang CY; Wu DD
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emodin inhibits epithelial‑mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC‑chemokine ligand 5 secreted from adipocytes.
    Song X; Zhou X; Qin Y; Yang J; Wang Y; Sun Z; Yu K; Zhang S; Liu S
    Int J Mol Med; 2018 Jul; 42(1):579-588. PubMed ID: 29693154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
    Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
    Wu C; Qiu S; Liu P; Ge Y; Gao X
    J Ethnopharmacol; 2018 Jan; 211():89-100. PubMed ID: 28962890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
    Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
    J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wnt/β-catenin signaling induces the transcription of cystathionine-γ-lyase, a stimulator of tumor in colon cancer.
    Fan K; Li N; Qi J; Yin P; Zhao C; Wang L; Li Z; Zha X
    Cell Signal; 2014 Dec; 26(12):2801-8. PubMed ID: 25193114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
    Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
    Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
    Cho TM; Kim JY; Kim YJ; Sung D; Oh E; Jang S; Farrand L; Hoang VH; Nguyen CT; Ann J; Lee J; Seo JH
    Cancer Lett; 2019 Apr; 447():141-153. PubMed ID: 30703411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
    Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
    Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the cystathionine γ lyase/hydrogen sulfide pathway in human melanoma progression.
    Panza E; De Cicco P; Armogida C; Scognamiglio G; Gigantino V; Botti G; Germano D; Napolitano M; Papapetropoulos A; Bucci M; Cirino G; Ianaro A
    Pigment Cell Melanoma Res; 2015 Jan; 28(1):61-72. PubMed ID: 25205294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins upregulate cystathionine γ-lyase transcription and H2S generation via activating Akt signaling in macrophage.
    Xu Y; Du HP; Li J; Xu R; Wang YL; You SJ; Liu H; Wang F; Cao YJ; Liu CF; Hu LF
    Pharmacol Res; 2014 Sep; 87():18-25. PubMed ID: 24951966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis.
    Su JC; Mar AC; Wu SH; Tai WT; Chu PY; Wu CY; Tseng LM; Lee TC; Chen KF; Liu CY; Chiu HC; Shiau CW
    Sci Rep; 2016 Jul; 6():28888. PubMed ID: 27364975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
    Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
    Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
    Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
    Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.